SANOVO
Start here
The Phase III SANOVO trial evaluated first-line osimertinib combined with savolitinib against osimertinib alone in advanced EGFR-mutated non-small cell lung cancer showing MET overexpression. In the intention-to-treat population, the combination reduced the risk of progression or death by 44% compared with osimertinib monotherapy. Both progression-free survival and overall survival improved with the combination, marking it as a potential first-line option for this patient subgroup. Where the data now stand, the headline efficacy results have been reported; detailed figures such as median PFS and OS values, subgroup outcomes, and safety findings have not yet been disclosed in the available coverage. Regulatory submissions based on SANOVO have not been announced.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickPhase III SANOVO Shows Osimertinib Plus Savolitinib Improves PFS and OS as First-Line Treatment in MET-Overexpressed EGFR-Mutated Advanced NSCLC
The Phase III SANOVO trial showed that first-line osimertinib plus savolitinib in advanced EGFR-mutated NSCLC with MET overexpression reduced the risk of progression or death by 44% versus osimertinib monotherapy in the ITT population, with improvements in both PFS and OS.
Heat trend for this story
Heat now 92·Peak in the comparable set 99 (Oct 26 22:00)·Change over 24h in the comparable set –·Participants now 12
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.